Omeros Q1 net loss $33.7M; receives $200M milestone; OMS906 data positive in PNH

OMEROS CORP

2023-Q1 EPS reported -$0.54

Net loss $33.7M ($0.54 per share) vs $33.0M ($0.53) Q1 2022; cash burn $23.6M excl $200M milestone.
Received $200M milestone from Rayner; OMIDRIA royalties $9.2M on $30.7M sales (down from $13.8M on $27.7M).
Plans BLA resubmission for narsoplimab in TA-TMA; meeting with FDA this month.
OMS906 in PNH: mean Hgb increased 3.4 g/dL at day 29; 100% of patients Hgb >=15.7 g/dL at day 113.
Awarded $6.69M NIDA grant for OMS527 in cocaine use disorder.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OMEROS CORP reported the first quarter ended March 31, 2023 results: net income Net loss was $33.7 million in the first quarter of 2023, or $0.54 per share, EPS $0.54 per share.

Period: the first quarter ended March 31, 2023
Net income: Net loss was $33.7 million in the first quarter of 2023, or $0.54 per share
EPS: $0.54 per share
Result: reported results

Exact text from the filing

Net loss was $33.7 million in the first quarter of 2023, or $0.54 per share

View on SEC.gov

Browse all earnings releases →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001558370-23-008805

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.